Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

Lamichhane, N.; Melas, Nikolaos; Bergqvist, Viktoria; , SWIBREG; Ekholm, Nils-Olof; Olén, Ola; F. Ludvigsson, Jonas; Hjortswang, Henrik; Marsal, Jan; Eriksson, Carl; Halfvarson, Jonas

doi:10.1007/s10620-024-08422-9

Public

Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

Published in Digestive Diseases and Sciences • Apr 18, 2024

Authors:

N. Lamichhane

Nikolaos Melas

Viktoria Bergqvist

Abstract

BACKGROUND: Real-world data on starting intravenous (IV) vedolizumab (VDZ) and transitioning to subcutaneous (SC) treatment in inflammatory bowel disease (IBD) are scarce. AIMS: To assess treatment outcomes of patients with IBD starting IV VDZ and switching to SC VDZ in routine clinical care. METHOD...

Subject

Vedolizumab

Medicine

Hepatology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!